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Abstract
Although neither kinase-dead human epidermal growth factor
receptor (HER)3 nor orphan HER2 can be activated by HER-
related ligands on their own, the formation of HER2/HER3
heterodimers creates the most mitogenic and transforming
receptor complex within the HER (erbB) family of transmembrane
receptor tyrosine kinases. The incorporation of markers such as
HER3 transactivation, HER2/HER3 dimer, or others that may
provide information regarding the level of HER pathway engage-
ment has been demonstrated to allow identification of patients who
respond to or escape HER-targeted therapies. Pioneering studies
showed that high expression of kinase-dead HER3 can predict
early escape from the anti-HER2 monoclonal antibody trastuzu-
mab. Also, the growth-inhibitory effects of HER1/2 tyrosine kinase
inhibitors (TKIs) were previously found to be attenuated in the
presence of heregulin, which is a high-affinity combinatorial ligand
for HER3. All of these concepts are being revisited with respect to
the efficacy of HER family TKI therapies; in particular, HER3
signalling buffered against incomplete inhibition of HER2 kinase
activity has been suggested to be the mechanism that allows
HER2 over-expressing breast cancer cells to escape HER TKIs. It
remains to be elucidated whether reactivation of HER3 signalling
can also account for the poor efficacy of HER TKIs in treating
breast carcinomas that contain low overall levels of HER2
receptors. However, it appears that regardless of the mechanism
that triggers the formation of oncogenic HER2/HER3 heterodimers
(HER2 over-expression or overall low HER2 but high levels of the
HER3 ligand heregulin), HER3 transphosphorylation is a common
response of breast cancer cells upon treatment with current
inhibitors of the HER receptor tyrosine kinase network. Because
kinase-inactive HER3 is not presently an amenable target for
forthcoming HER TKIs, molecular approaches that can efficiently
block heregulin-triggered HER3 transactivation or nucleo-
cytoplasmic trafficking of heregulin might offer novel strategies
with which to manage HER-driven breast cancer disease.
The notion that breast cancer disease can be viewed as a
biological process that is driven by overactive human
epidermal growth factor receptor (HER)1/2 receptor tyrosine
kinases (RTKs) has led to development of various anti-HER
tyrosine kinase agents. Several of these have undergone
clinical trials, including low-molecular-weight inhibitors with
highly selective and reversible tyrosine kinase inhibiting
properties [1-5]. Unfortunately, following much clinical and
basic science research, we have learned that simple
measurement of overactive HER tyrosine kinases does not
predict HER TKI efficacy. Initial phase II studies [3,4]
demonstrated that the HER1 tyrosine kinase inhibitor (TKI)
gefitinib did not have high efficacy in heavily pretreated
populations of patients with metastatic breast cancer,
particularly after chemotherapy. With few exceptions, clinical
studies of the HER1 TKI gefitinib in breast cancer have
demonstrated poor clinical responses and a disease control
rate of approximately 10%. Indeed, tumour responses
induced by HER1 TKIs are infrequent and transient, with
sensitive patients rapidly developing secondary resistance.
Therefore, molecular criteria for predicting sensitivity to HER
TKIs are needed to allow appropriate use of these agents and
to facilitate planning of future research.
Failure to reverse breast cancer progression despite apparent
inhibition of HER1 and HER2 kinase functions in cell-based
assays as well as in patient tissues and tumours is an enigma
that is not yet resolved [6]. Although it is kinase defective, the
HER family member HER3 can be phosphorylated by HER1
or HER2, and HER3 can couple with the pro-survival phos-
phatidylinositol-3-OH kinase (PI[3]K)/Akt pathway directly
whereas HER1 and HER2 cannot [5] (Figure 1). Based on
these findings, Sergina and coworkers [6] recently suggested
that HER3, and consequently the PI(3)K/Akt pathway, evade
inhibition by current HER family TKIs via a compensatory shift
in the HER3 phosphorylation/de-phosphorylation equilibrium
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[6] (Figure 2). In their hands, Akt-mediated negative feedback
signalling appeared to promote increased membrane HER3
(driving the phosphorylation reaction) and to reduce HER3
phosphatase activity (impeding the de-phosphorylation
reaction). They therefore concluded that the biological marker
used to assess the efficacy of HER TKIs should be trans-
phosphorylation of HER3, rather than autophosphorylation of
HER1 or HER2 [6].
Although neither kinase-dead HER3 nor orphan HER2 can be
activated by HER-related ligands on their own, the formation
of ligand-independent and ligand-dependent HER2/HER3
heterodimers creates the most mitogenic and transforming
receptor complex within the HER family of transmembrane
RTKs [1,5,7-9]. Moreover, inhibition of HER3 transphos-
phorylation or its preferential cross-talk with HER2 is known
to be required for the antitumour effect of HER2 signalling
inhibitors [10-12] (Figure 1). High expression of HER3 was
previously shown to predict early escape from HER-targeted
therapies using, for instance, the anti-HER2 monoclonal
antibody trastuzumab [13]. However, incorporation of markers
such as HER3 transactivation, HER2/HER3 dimer, or others
that may provide information regarding the level of HER
pathway engagement and so allow identification of patients
who respond to or escape HER-targeted therapies has
already been proposed [12,13]. We previously demon-
strated, in breast cancer cells exhibiting enhanced HER3
signalling, that specific anti-HER2 strategies (namely trastu-
zumab) efficiently interfere with the lateral signalling between
HER3 and HER2, shutting down the ability of HER3/HER2
heterodimers to function as an ’oncogenic unit‘ [11].
All of these findings are now being revisited with respect to
the efficacy of HER family TKI therapy, with HER3 signalling
buffered against incomplete inhibition of HER2 kinase activity
being suggested to be the mechanism that allows HER2
Figure 1
Mechanisms of HER2/HER3 activation in breast cancer cells. It is
generally accepted that spontaneous homodimerization and activation
of human epidermal growth factor receptor (HER)2 occurs in breast
cancer cells with HER2 gene amplification. Another potential
mechanism of HER2 phosphorylation is transactivation by ligand
(autocrine/paracrine heregulin)-bound HER3. Although HER2 does not
bind any of the HER ligands directly (including heregulin), its catalytic
activity potently amplifies signalling by HER-containing heterodimers
via increasing ligand binding affinity or receptor recycling and stability.
On the other hand, although it is kinase defective, HER3 can be
phosphorylated by HER2. Phosphorylated HER3 can couple to the
phosphatidylinositol-3-OH kinase (PI[3]K)/Akt pathway directly,
whereas HER2 cannot. Therefore, neither orphan (ligandless) HER2
nor tyrosine kinase (TK) dead HER3 can be activated by HER-related
ligands on their own. However, the formation of ligand-independent
and ligand-dependent HER2/HER3 heterodimers creates the most
mitogenic and transforming receptor complex within the HER family of
transmembrane receptor tyrosine kinases (RTKs). In HER2 over-
expressing breast cancer cells, HER tyrosine kinase inhibitors (TKIs)
inhibit basal phosphorylation of HER3 and its association with HER2
and with PI(3)K. Cyt, cytoplasm; ECM, extracellular milieu; Nu, nucleus.
Figure 2
Biological markers to assess the efficacy of HER TKIs (I): Akt-regulated
HER3 phosphorylation-dephosphorylation equilibrium. The study
conducted by Sergina and coworkers [6] suggests that the biological
marker used to assess the efficacy of human epidermal growth factor
receptor (HER) tyrosine kinase inhibitors (TKIs) should be
transphosphorylation of HER3 rather than autophosphorylation of
HER1 or HER2 [6]. They reported that HER3 and phosphatidylinositol-
3-OH kinase (PI[3]K)/Akt signalling is not effectively inhibited by
current HER TKIs. Through Akt-mediated negative feedback signalling,
a compensatory shift occurs in the HER3 phosphorylation-
dephosphorylation equilibrium, driven by increased HER3 membrane
expression (phosphorylation reaction) and by reduced HER3
phosphatase activity (dephosphorylation reaction). Despite significant
inhibition of HER2 activity, the reactivation of HER3 signalling to a new
steady-state HER3 phosphorylation level requires much higher
concentrations of HER TKIs because the un-inhibited HER3
phosphorylation state is significantly higher in this new steady state.
Therefore, although kinase-inactive HER3 is not a direct target of HER
TKIs, HER3 substrate resistance appears to undermine their efficacy
significantly.Page 3 of 5
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over-expressing breast cancer cells to escape from HER TKIs
(Figure 2). Using HER2 over-expressing breast cancer cells,
Sergina and coworkers [6] similarly reported that TKI
refractory HER3 phosphorylation is due to HER2 because it
can be suppressed by anti-HER2 small interfering RNA
transfection. It should be noted that Sergina and coworkers
employed mono-specific HER1 reversible TKIs (for instance,
gefitinib and erlotinib) and pan-HER irreversible inhibitors (for
example, CI-1033 [canertinib]). However, these HER TKIs
may be suboptimal for management of HER2 over-expressing
breast carcinomas [14,15]. Moreover, many so-called HER
specific inhibitors (including gefitinib, erlotinib and canertinib)
have been found to be rather promiscuous kinase inhibitors,
binding several non-HER kinases at similar affinities to their
target HER1 [14,15]. Whether HER3 transphosphorylation
can allow HER2 over-expressing breast cancer cells to
escape bi-specific HER1/HER2 reversible TKIs such as
GW572016 (lapatinib; the most specific inhibitor, binding its
intended targets, namely HER1 and HER2, with high affinity)
remains to be elucidated.
Another important issue that was not addressed in the study
conducted by Sergina and coworkers [6] is whether
reactivation of HER3 signalling can also account for the
inefficacy of HER TKIs against HER1-positive breast
carcinomas that contain low overall levels of HER2 receptors,
which represent a subset of extremely aggressive tumours
[2,3,5]. In fact, we recently reported that two apparently
distinct breast cancer populations, one over-expressing
HER2 with low levels of the HER3 transactivator heregulin
and the other over-expressing heregulin but not HER2,
indeed employ the same signalling pathway (HER3 →
PI[3]K/Akt) to control breast cancer cell responses to anti-
HER2 therapeutics [11,12]. Because epidermal growth
factor (EGF)-related ligands activate different HER receptors,
and most tumours of epithelial origin express multiple HER
receptors and co-express one or more of the HER-related
ligands, multiple HER receptor combinations might be active
in a tumour. This characteristic should influence tumour
response to a HER-targeted therapeutic; therefore, the
efficacy of anticancer drugs that block a single HER receptor
may be compromised by the presence of EGF-related
ligands. In this regard, Motoyama and colleagues [16]
conducted pioneering work in demonstrating that the growth-
inhibitory effects of HER1/2 TKIs are significantly attenuated
in the presence of exogenous heregulin, which is a high-
affinity combinatorial ligand for the HER3 and HER4
receptors in breast cancer cells. Accordingly, the antitumour
actions expected to result from pharmacological blockade of
HER2/HER3 dimer can be entirely mimicked by specifically
blocking the autocrine expression of heregulin. In vitro, anti-
heregulin strategies (antisense cDNA heregulin transfection
and structural deletions that impair the autocrine activity of
heregulin) significantly block HER3/HER2 transactivation and
deactivate anti-apoptotic PI(3)K/Akt signalling [11,17,18]. In
vivo, heregulin-induced HER3/HER2 transactivation, in the
absence of HER2 over-expression, is sufficient for generation
of adenocarcinomas while favouring the metastatic spread of
breast cancer cells in mice [19]. Furthermore, blockade of the
heregulin/HER3 signalling pathway reduces tumour formation
and size and suppresses metastasis [20].
Within the context of HER-targeting inhibitors, it has been
observed that breast cancer cells with acquired resistance to
the anti-HER2 monoclonal antibody trastuzumab express
higher endogenous levels of EGF-related ligands as com-
pared with parental, trastuzumab-sensitive cells [12]. More-
over, Schaefer and colleagues recently demonstrated that the
growth-inhibiting effects of the pan-HER TKIs CI-1033 and
PD158780 indeed correlate with expression levels of the
HER ligand heregulin [21]. Hence, those investigators
identified an autocrine growth stimulation loop that may
represent an interesting target for new therapeutic strategies
in HER TKI refractory tumours. In our laboratory, when breast
cancer cells intrinsically resistant to gefitinib (HER2-negative
MCF-7 cells) were engineered to exhibit constitutively an
autocrine heregulin loop (MCF-7 cells were forced to over-
express heregulin endogenously), they exhibited further a
twofold to threefold increase in the 50% inhibitory
concentration of gefitinib. This heregulin-enhanced HER TKI
refractory phenotype was accompanied by persistent ‘HER3
superphosphorylation’, an enormous upregulation of the
PI(3)K p85 regulatory subunit, and downstream
hyperactivation of Akt (Menendez JA, Lupu R, unpublished
data). Therefore, the impact of HER2 on both the biological
behaviour of breast cancer and responses to HER-targeting
therapies is better appreciated when one considers not only
the presence of HER2 over-expression but also the presence
of active forms of other HER receptors (especially HER3), the
expression levels of HER3/HER4 ligands and the activation
status of downstream transduction cascades [11,12,22].
That TKI-induced forward shift in HER3 steady-state
phosphorylation is driven by HER3 re-localization to the
plasma membrane and that it can be suppressed by inhibitors
of vesicular trafficking might also relate to the HER3 ligand
heregulin. Offterdinger and coworkers [23] previously
demonstrated that heregulin not only profoundly affects
HER3 function (in an autocrine manner) but also further
regulates (in an intracrine manner) HER3 subcellular distri-
bution. This affect occurs via induction of nucleolar and
nuclear export of HER3, anchoring it to non-nuclear
structures, and consequently leading to a slow enrichment of
HER3 in the cytoplasm/membrane compartments and its
deprivation in the nucle(ol)us [23] (Figure 3). Sergina and
coworkers [6] observed that the HER3 pool, largely within
intracellular compartments (including cell nuclei), exhibits
significantly increased expression at the plasma membrane
upon gefitinib treatment.
Similarly to HER3 silencing in HER2 over-expressing breast
cancer cells, we recently reported that experimental ablation
Available online http://breast-cancer-research.com/content/9/5/111of heregulin by small interfering RNA triggers potent pro-
apoptotic activity in otherwise cytostatic gefitinib in low
HER3 expressing MDA-MB-231 cells. This surprising finding
suggests that a causal connection may also exist between
intracrine heregulin and breast cancer cell responses to HER
TKIs. This hypothesis was partially validated by monitoring
gene expression profiles and subcellular localization of HER-
related ligands before and after gefitinib treatment. Using
real-time reverse transcription polymerase chain reaction,
Ferrer-Soler and coworkers [24] characterized gefitinib-
resistant and gefitinib-sensitive breast cancer cell lines
according to mRNA expression of EGF-related ligands before
and after gefitinib exposure. When expression data were
normalized relative to ribosomal RNA (18S RNA) as the
endogenous control gene, HER1 over-expressing MDA-MB-
468 cells (the main HER1-positive breast cancer model of
gefitinib resistance) were found to exhibit significantly up-
regulated (by up to eight times) levels of the HER3 ligand
heregulin. Conversely, expression of heregulin was completely
abolished in HER2 over-expressing SKBR3 cells, which are
exquisitely sensitive to gefitinib. A second finding was that
gefitinib-resistant MDA-MB-468 cells exhibited a striking
nuclear accumulation of heregulin following gefitinib exposure.
Conversely, gefitinib treatment significantly reduced dot-like
structures containing heregulin in the nuclei of gefitinib-
sensitive SKBR3 cells [24]. Third, prevention of heregulin
transport to the nucleus by deleting its nuclear localization
signal [25,26] not only obviated the ability of heregulin to
enhance resistance to gefitinib but also further disrupted
HER2/HER3 cross-talk in MCF-7 breast cancer cells
(Menendez JA, Lupu R, unpublished observations).
Thus, changes in heregulin subcellular compartmentalization
modify the activation status of the HER3/HER2 dimer (and, in
turn, efficacy of HER TKIs), probably through alterations in
the nucleocytoplasmic shuttling or the endosomal sorting of
HER RTKs (Figure 3). Moreover, intracrine/nuclear heregulin
might also bypass the antiproliferative effects of HER-
directed TKIs without need for activation of specific HER RTK
members or HER network-driven activation of downstream
signalling cascades. This ‘direct mode’, involving active
transport of the HER3 ligand heregulin to the cell nucleus
and its association with and regulation of target genes or
nuclear proteins, warrants further studies because it might
demonstrate even greater complexity of the breast cancer
’HER TKIs’ scenario [27,28].
It is unclear at this time how to select a population of breast
cancer patients who are most likely to be sensitive to HER
TKIs. The study conducted by Sergina and coworkers [6]
suggests that the biological marker used to assess the
efficacy of HER TKIs should be transphosphorylation of
HER3, rather than autophosphorylation of HER1 or HER2.
Certainly, regardless of the mechanism that triggers the
formation of HER2-containing heterodimers (HER2 over-
expression or overall low HER2 but high levels of the auto-
crine/paracrine HER3 ligand heregulin), HER3 transphos-
phorylation appears to be a common response of breast
cancer cells upon pharmacological disturbance of the HER
RTK network. On the other hand, virtually nothing is known
about the paracrine/autocrine/intracrine actions of HER
ligands that are involved in the efficacy of HER TKIs.
Auspiciously, two up-to-date reports have begun to shed light
on the clinical implications of the HER3 ligand heregulin as a
previously unrecognized modulator of the effectiveness of
anti-HER therapies. First, de Alava and coworkers [29]
recently demonstrated that over-expression of trans-
membrane heregulin significantly correlated with a longer
event-free survival and overall survival in patients with low or
normal HER2 expression who were treated with the mono-
specific HER2 inhibitor trastuzumab. However, this was not
the case in patients with HER2 over-expression. Second,
Breast Cancer Research    Vol 9 No 5 Menendez and Lupu
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Figure 3
Biological markers to assess the efficacy of HER TKIs (II): intracrine/
nuclear functions of the HER3 ligand heregulin. The intrinsic or
acquired ability of breast cancer cells to specifically regulate the
expression and/or the subcellular compartmentalization of the human
epidermal growth factor receptor (HER)3 ligand heregulin might
represent a previously unrecognized mechanism that regulates the
efficacy if HER tyrosine kinase inhibitors (TKIs). In one hand, heregulin
has been found to promote slow enrichment of HER3 in the
cytoplasm/membrane compartments and its deprivation in the
nucle(ol)us [23]. This intracrine mechanism of action may significantly
increase HER3 membrane expression and, therefore, the HER3
phosphorylation reaction. On the other hand, a ‘direct mode’ that
involves active transport of heregulin to the cell nucleus, and its
association with and regulation of target genes or nuclear proteins may
add even more complexity to the breast cancer ‘HER-TKIs’ scenario,
because it might bypass the antiproliferative effects of HER-directed
TKIs without need for the activation of specific HER receptor tyrosine
kinase members and/or HER network-driven activation of downstream
signalling cascades [24-28].Hutcheson and colleagues [30] recently reported that
heregulin efficiently overcomes the cell growth and invasion
inhibitory effects of the mono-specific HER1 inhibitor gefitinib
in tamoxifen-resistant breast cancer cells through promotion
of HER2/HER3 heterodimerization and activation of the
PI(3)K/Akt signalling pathway.
Because HER3 is kinase inactive, it is not a direct target of
TKIs and cannot at present be targeted readily with drug
treatment [31]. Alternatively, future therapies aimed at
avoiding ligand-triggered HER3 transactivation, alongside a
better understanding of the therapeutic relevance of
paracrine/autocrine/intracrine expression and
nucleocytoplasmic trafficking of heregulin, may offer novel
approaches with which to manage HER-driven breast cancer
disease.
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